泰凌醫藥(01011.HK)與湖北某市政府簽訂框架協議
格隆匯5月17日丨泰凌醫藥(01011.HK)宣佈,於2022年4月29日,公司與中國湖北省某城市的市政府("市政府")及一家在中國註冊成立的公司簽訂框架協議。
中國政府一直重視中國健康及福利體系的現代化,並於近期推出了"第十四個五年"發展規劃,以鼓勵製藥行業發展新技術。與市政府訂立的框架協議被視為中國政府實施該政策的眾多步驟之一。
根據框架協議,市政府擬投資於公司多項研發項目。特別是,(i)公司擬與中國湖北省某市的市政府在高新區("高新區")成立一家合資公司("合資公司")作為其新總部,而該公司為專門研發、生產及銷售及服務的綜合生物科技製藥公司,將會投資於(a)全球一流的生物新藥;(b)若干藥品許可權;及(c)精神科人工智能篩選技術等資產及科技,且預期合資公司將為公司的附屬公司,並將公司現有的製造能力轉移至合資公司;(ii)市政府擬在高新區提供一幅土地,用於設立供合資公司使用的廠房及設施;(iii)市政府亦擬提供約人民幣2億元的資金,用於設立合資公司使用的廠房及設施;及(iv)市政府或其指定平台將向合資公司投資約人民幣3億元,以持有合資公司不超過15%的股權,退出期限為三年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.